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2. Introduction  
2.1. Pulmonary hypertension 
 
2.1.1. Definition and symptoms 
The term pulmonary hypertension (PH) refers to a condition where the mean pulmonary 
artery pressure exceeds 25 mmHg at rest or 30 mmHg during exercise (Barst, McGoon 
et al. 2004) (Peacock, Murphy et al. 2007) or where the pulmonary artery systolic 
pressure is measured above 35 mmHg (Barst, McGoon et al. 2004). The patients with 
pulmonary hypertension present with symptoms as dyspnoe, syncope or angina, first 
during exercise and at later stages of the disease at rest also (Subias, Mir et al. 2010). 
Although there are treatment possibilities, most patients eventually die from the disease 
(Morrell, Adnot et al. 2009). 
 
2.1.2. Incidence and prevalence 
Pulmonary arterial hypertension (PAH) has an incidence of 1-2 cases per million. Most 
cases are women in their 3rd and 4th decade of life. The male to female ration is 1:1.7 
(Haoula, Hief et al. 2006). In France a prevalence of 5-25 cases per million adults were 
found, depending on the region (Humbert, Sitbon et al. 2006). 
 
2.1.3. Classification 
In 1973 the World Health Organization invited for a meeting in Geneva to discuss on 
primary pulmonary hypertension (PPH). Reason for this meeting was an observed 
increase of patients with PH in Switzerland, Germany and Austria. The topic of 
Secondary pulmonary hypertension was not part of the meeting (Hatano and Strasser 
1975). Classification of PH was revised at different points in time. The actual 
classification of PH is the Dana Point classification. On the 4th World Symposium on 
PH in Dana Point in 2008 experts decided to adjust the classification of pulmonary 
hypertension to literature and for clarification of some passages (table 2.1.). This 
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classification is based on the Evian-Venice classifications from the 2nd and 3rd World 
Symposiums on pulmonary arterial hypertension (Simonneau, Robbins et al. 2009).  
 
2.1.4. Pathology 
In PAH the small pulmonary arteries are affected. The pulmonary circulation is referred 
to as low pressure system (Humbert, Morrell et al. 2004) where the normal pulmonary 
artery has few muscle fibers (Gaine and Rubin 1998). In PAH the diameter of the artery 
lumen decreases while the resistance increases. This leads to right heart failure 
(Humbert, Morrell et al. 2004). The disease can occur at any age. PAH in smaller 
children also comes along with not correctly dilating vasculature at birth. Older patients 
suffer from a progressing muscularisation of distal vessels, hyperplasia of the intima, 
the formation of plexiform lesions and changes in the endothelium. The number of 
distal vessels decreases (Rabinovitch 2008). Intima, media and adventitia are involved 
in vascular remodelling (Chazova, Loyd et al. 1995). Archer and Rich (Archer and Rich 
2000) summarize excess of endothelial production of constrictor versus dilator 
prostaglandins, excess of endothelin-1 (ET-1) versus nitric oxide (NO), excessive 
thrombosis in situ, serotonin excess, K+ channelopathy of pulmonary artery smooth 
muscle cells (PASMCs) and platelets, dysregulated elastase and matrix 
metalloproteinases (MMPs) as well as monoclonal proliferation of endothelial cells as 
possible causes for PPH. 
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1.  Pulmonary arterial hypertension (PAH) 
1.1.  Idiopathic PAH 
1.2.  Heritable 
1.2.1.  BMPR2 
1.2.2.  ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3.  Unknown 
1.3.  Drug- and toxin-induced 
1.4.  Associated with 
1.4.1.  Connective tissue diseases 
1.4.2.  HIV infection 
1.4.3.  Portal hypertension 
1.4.4.  Congenital heart diseases 
1.4.5.  Schistosomiasis 
1.4.6.  Chronic hemolytic anemia 
1.5.  Persistent pulmonary hypertension of the newborn 
1`.  Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH) 
 
2.  Pulmonary hypertension owing to left heart disease 
2.1.  Systolic dysfunction 
2.2.  Diastolic dysfunction 
2.3.  Valvular disease 
 
3.  Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1.  Chronic obstructive pulmonary disease 
3.2.  Interstitial lung disease 
3.3.  Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4.  Sleep-disordered breathing 
3.5.  Alveolar hypoventilation disorders 
3.6.  Chronic exposure to high altitude 
3.7.  Developmental abnormalities 
 
4.  Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5.  Pulmonary hypertension with unclear multifactorial mechanisms 
5.1.  Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2.  Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis:        
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3.  Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
5.4.  Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on 
dialysis 
 
Table 2.1. Clinical classification of pulmonary hypertension (Dana Point, 2008), 
(adapted from Simonneau, Robbins et al. 2009, permission license number 
2980771152024 from Elsevier via Copyright Clearance Center). 
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2.1.4.1. Causes on cellular basis 
Medial hypertrophy and thickening of adventitia and intima are referred to as 
constrictive lesions. As reason failure in the systems of apoptosis and proliferation are 
considered. Changes in the media involve hypertrophy and hyperplasia of smooth 
muscle cells (SMCs), a gain in connective tissue matrix and elastic fibers and the move 
of SMCs in previously not muscularized arteries. Intimal thickening involves 
fibroblasts, myofibroblasts and SMCs (Pietra, Capron et al. 2004). 
Another feature of PH are plexiform lesions. The reasons for the development of 
plexiform lesions are not known. It is believed that shear stress, hypoxia, inflammation, 
drugs and toxins could play a roll if the patient shows genetic predisposition (Humbert, 
Morrell et al. 2004). Plexiform lesions consist of diverse phenotypes of endothelial 
cells. The existence of one plexiform lesions can lead to severe occludence of the entire 
vessel (Cool, Stewart et al. 1999).  
For vascular integrity endothelial cells are very important. Altered function of 
endothelial cells leads to disequilibrium in production of vasoconstrictors and 
vasodilators, activators and inhibitors of SMC growth and migration, prothrombotic/ 
antithrombotic and proinflammatory/ anti-inflammatory signals (Morrell, Adnot et al. 
2009) (figure 2.1.). 
 
2.1.4.2. Causes on genetic basis 
PAH also is related to the genes activin receptor-like kinase 1 (ALK1), Endoglin and 
bone morphogenetic protein receptor II (BMPRII) (compare table 1.1). Studies showed 
that mutations in the BMPRII gene cause PAH (Lane, Machado et al. 2000) (Deng, 
Morse et al. 2000) while ALK1 and Endoglin are related to PAH via hereditary 
haemorrhagic telangiectasia (HHT). This disease is characterized by vascular 
abnormalities which cause easy bleedings (Haitjema, Westermann et al. 1996). Two 
kinds of HHT are known, HHT type 1 and HHT type 2. The causes for HHT type 1 and 
HHT type 2 are mutations in Endoglin and ALK1 respectively (Abdalla and Letarte 
2006). Some patients with HHT also suffer from PH. This kind of PH can show the 
same clinical and histological characteristics as PPH (Trembath, Thomson et al. 2001 
and references therein). Investigations show that association between PAH and HHT 
mostly occurs in patients with ALK1 signalling defects (Harrison, Flanagan et al. 2003). 
Also it has been suggested that mutations in Endoglin contribute to PAH (Chaouat, 
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Coulet et al. 2004). It has been implicated that mutations in BMPRII, ALK1 and 
Endoglin are causal factors of hereditary and associated forms of PAH (Machado, 
Eickelberg et al. 2009 and reference therein). 
 
Several different parameters add to the pathobiology of PAH. It is not likely that one 
factor or mutation can explain all cases of PAH (Humbert, Morrell et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Pathobiology of PH. Different vascular abnormalities associated with PH 
compared with normal pulmonary circulation (Rabinovitch 2008, permission 
confirmation number 11025786 from AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION via Copyright Clearance Center). 
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2.2. Investigation of vascular remodelling  
 
For vascular remodelling and proliferation hypoxia is an accepted cause. Commonly the 
hypoxia-model serves as model for investigation on pulmonary vascular remodelling. 
The hypoxia-model is – compared to the also widely used monocrotaline-model - a 
more physiological model. At high altitudes hypoxia is the stimulus for development of 
PH and at sea level it occurs as a consequence of hypoxic lung diseases. Monocrotaline 
induced PH does not exist in nature (Pak, Aldashev et al. 2007). 
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2.3. Transforming growth factor β (TGF-β) signalling pathway 
 
2.3.1. Overview 
The TGF-β signalling pathway has been summarized by Massague: The TGF-β ligand 
binds to a type II receptor. Together with a type I receptor, a receptor complex is 
formed and the type I receptor gets phosphorylated. Then the type I receptor 
phosphorylates the receptor-regulated Smads (R-Smads) which form a complex with 
Smad4 (also named Co-Smad) and translocate into the nucleus. There they contribute to 
gene expression (Massague 1998) (figure 2.2.). 
 
2.3.2. TGF-β family 
TGF-β plays a role in a lot of cell processes such as wound healing (Sporn, Roberts et 
al. 1983) and tissue repair (Roberts, Sporn et al. 1986), embryogenesis (Heine, Munoz 
et al. 1987), regulation of inflammatory and immune response (Sporn 1999), 
extracellular matrix deposition (Miyazono, Olofsson et al. 1991) as well as in cell 
division, differentiation, migration, adhesion, organization and death (Massague, 
Seoane et al. 2005). 
The TGF-β family consists of more than 60 members (Feng and Derynck 2005), such as 
nodals, activins, bone morphogenetic proteins (BMP), anti-Muellerian hormone (AMH) 
(Shi and Massague 2003; Massague and Gomis 2006), growth differentiation factors 
(GDF) (Shi and Massague 2003) and myostatin (Massague and Gomis 2006). Up to 42 
members of the TGF-β family are expected to be present in human (Feng and Derynck 
2005). Three isoforms of TGF-β could be identified in human: TGF-β1, TGF-β2 and 
TGF-β3. In chicken TGF-β4 and in frogs TGF-β5 have been characterized also 
(Miyazono, Olofsson et al. 1991). 
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Figure 2.2. TGF-β signalling pathway. R-Smad: receptor dependent Smad; I-Smad: 
inhibitory Smad; Co-Smad: collaborator Smad. ALK1 and Endoglin refer to the 
development of HHT (Fernández-L, Sanz-Rodriquez et al. 2006, permission 
confirmation number 11025810 from MARSHFIELD CLINIC via Copyright 
Clearance Center).  
 
2.3.2.1. Transforming growth factor β 
TGF-β is synthesized as precursor protein (Lawrence, Pircher et al. 1985) (Pircher, 
Jullien et al. 1986); TGF-β1 precursor (pro-TGF-β1) is processed by the endoprotease 
furine (Dubois, Laprise et al. 1995). After being processed by the endoprotease, the 
propeptide (LAP, latency-associated peptide) and the mature TGF-β remain in a 
noncovalent association called small latent complex, which is inactive. For biological 
effects (e.g. interacting with TGF-β receptors) activation of TGF-β is necessary. This 
takes place by dissociation of TGF-β from the propeptide (LAP). Another possibility is 
that the small latent complex binds to the latent TGF-β binding protein (LTBP), then 
called large latent complex (Gleizes, Beavis et. al 1996). The LTBP binds LAP mainly 
covalently to the ECM (Taipale, Miyazono et al. 1994).  
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2.3.2.2. TGF-β receptors 
There are type I– and type II receptors. This classification is based on structure and 
function. Three groups of type I receptors are known in mammals. Group one contains 
TGF-β receptor I (TGF-βRI, also referred to as ALK5), activin receptor IB (ActRIB, 
also referred to as ALK4) and activin receptor-like kinase 7 (ALK7), group two bone 
morphogenetic protein receptor IA (BMPRIA, also referred to as ALK3) and bone 
morphogenetic protein receptor IB (BMPRIB, also referred to as ALK6), group three 
activin receptor-like kinase 1 (ALK1) and activin receptor-like kinase 2 (ALK2). The 
three groups are characterized by similarities in kinase domains and signalling 
(Massague 1998). Activin receptor IIA (ActRIIA), activin receptor IIB (ActRIIB), bone 
morphogenetic protein receptor II (BMPRII), anti-Muellerian hormone receptor II 
(AMHRII) and TGF-β receptor II (TGF-βRII) represent the type II receptors existing in 
human (Massague and Gomis 2006). Betaglycan and Endoglin act as auxiliary 
receptors, playing a role in response and binding of TGF-β (Feng and Derynck 2005). 
Cloning of Act-RII led to the observation that the receptor contains serine/ threonine 
protein kinase activity (Mathews and Vale 1991). TGF-βRI as well as TGF-βRII are 
transmembrane serine/ threonine kinases (Massague, Attisano et al. 1994). The kinase 
activity is supposed to be located in the cytoplasmatic domain of the receptors, which 
furthermore contain an amino-terminal signal peptide, a small extracellular region, a 
single hydrophobic transmembrane helix and a cysteine box in the extracellular domain 
(Kingsley 1994). 
 
2.3.2.3. Smads 
The name Smad results from a combination of the names of the first discovered 
effectors of this class in C. elegans Sma and Drosophila Mad (Derynck, Zhang et al. 
1998). Eight different Smads have been identified in mammals (Attisano and Lee-
Hoeflich 2001). It can be differentiated between receptor regulated Smads (such as 
Smad1/ Smad5/ Smad8 and Smad2/ Smad3), collaborating Smads (as Smad4) and 
antagonistic Smads (as Smad6/ Smad7). Between the groups, the Smads show similar 
structure and function (Massague 1998).  
An additional way of classifying Smads is the kind of receptors and ligands they are 
activated by. BMP type I receptors enable Smad1/ Smad5/ Smad8 for signalling, activin 
and TGF-β type I receptors Smad2 and Smad3. In both pathways Smad4 is involved 
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(Miyazono, Maeda et al. 2005). Nevertheless the pathway specificity for Smad1/ 
Smad5/ Smad8 and Smad2/ Smad3 cannot be seen totally strict since ALK1 has to 
signal through Smad1/ Smad5 and possibly Smad8 (Eickelberg and Morty 2007 and 
reference therein) (figure 2.3.). 
 
2.3.3. Role of ALK1 and ALK5 in endothelial cell (EC) migration and proliferation 
The formation of new vessels can take place as angiogenesis or vasculogenesis. The 
dominant form of new vessel formation in the adult is angiogenesis (Carmeliet 2000). 
Angiogenesis has a resolution and an activation phase. Usually the endothelium is in a 
quiescent state called the resolution phase. Mural and smooth muscle cells inhibit 
endothelial proliferation and enhance extracellular matrix production. This leads to a 
more stable vessel. The activation phase is characterized by detachment of smooth 
muscle cells and proliferation and migration of endothelial cells (Carmeliet 2000; 
Bertolino, Deckers et al. 2005).  
It has been shown that TGF-β signalling in ECs via ALK5 leads to inhibition of 
migration and proliferation, while TGF-β signalling via ALK1 leads to migration and 
proliferation (Goumans, Valdimarsdottir et al. 2002). High doses of TGF-β inhibit 
migration of EC while lower doses of TGF-β increase migration (Pepper, Vassalli et al. 
1993; Goumans, Valdimarsdottir et al. 2002). In ECs ALK-5 kinase activity is 
necessary for optimal ALK1 signalling (Goumans, Valdimarsdottir et al. 2003). 
Furthermore it has been shown that ALK1 signalling negatively influences TGF-β 
signalling by ALK5 (Oh, Seki et al. 2000).  
Other experiments however lead to the assumption that ALK1 inhibits proliferation and 
migration of ECs (Lamouille, Mallet et al. 2002). It could be shown that bone 
morphogenetic protein 9 (BMP9) as a ligand of ALK1 inhibited proliferation and 
migration of ECs and blocked vascular endothelial growth factor (VEGF)- induced 
angiogenesis (Scharpfenecker, van Dinther et al. 2007). BMP9 and BMP10 as ALK1 
ligands also inhibit migration of ECs (David, Mallet et al. 2007). These findings point to 
the idea that the effect of ALK1 signalling on angiogenesis depends on the context and 
specific ligand by which it is activated (Goumans, Liu et al. 2009).  
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Figure 2.3. Elements of the TGF-β/ BMP signalling pathway (Eickelberg and Morty 
2007, permission license number 2980771377592 from Elsevier via Copyright 
Clearance Center). 
 
2.3.4. Target genes of ALK1/ ALK5 
For ALK1 inhibitor of differentiation 1 (ID1) has been revealed as downstream target 
gene. Also it has been shown that ALK1 upregulates inhibitor of differentiation 2 (ID2) 
(Ota, Fujii et al. 2002) (Lux, Salway et al. 2006). Yang et al. suggest that “the failure of 
activation of ID gene expression in mutant PASMCs may contribute to abnormal 
pulmonary vascular cell proliferation in familial PAH” (Yang, Davies et al. 2008).  
For ALK5 plasminogen activator inhibitor-1 (PAI-1) serves as target gene (Goumans, 
Valdimarsdottir et al. 2002). PAI-1 is involved in vascular remodelling. Depending on 
the circumstances it leads to increase or decrease of vascular remodelling (Diebold, 
Kraicun et al. 2008). Nevertheless a significant decrease of PAI-1 in PASMC in 
idiopathic pulmonary arterial hypertension (IPAH) was reported, and furthermore, that 
PAI-1 inhibits proliferation and enhances migration of PASMC (Kouri, Queisser et al. 
2008). 
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2.3.5. TGF-β family components in hypoxia induced PH in mice and in IPAH  
Mice were exposed to hypoxia for 2, 7 and 21 days and lung homogenates were 
investigated. After 21 days of hypoxia a downregulation of ALK1, ALK3, TGF-βRII, 
Smad7 and Smad8 was found on mRNA level. The same experiment revealed a 
significant downregulation of ALK1, TGF-βRII, Smad1 and Smad4 on protein level 
after 21 days of hypoxia. 
Lungs from IPAH patients compared to donor lungs showed a significant 
downregulation of ALK1 of mRNA obtained from lung homogenates (Amarie 2009). 
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3. Aim of the study 
PASMCs are implicated in the development of PAH. We hypothesized that alterations 
in the TGF-β signalling pathway of hPASMCs, especially altered ALK1 signalling, play 
a role in the development of PAH. To imitate the situation in PAH, the cells were 
exposed to hypoxia. 
Aims of the study were  
 to identify members of the TGF-β family in hPASMCs with changes in 
expression in hypoxia compared to normoxia 
 to identify ALK1 dependent processes in hPASMCs exposed to hypoxia that 
could influence the development of PAH 
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4. Material and Methods 
4.1. Material 
 
4.1.1. Equipment 
Amersham HyperfilmTM ECL GE Healthcare Limited, UK 
ABI PRISM 7500 Detection System    Applied Biosystems, USA 
Heraeus Biofuge Fresco DJB Labcare Limited, 
England 
Curix HT1.000G PLUS     AGFA, Belgium 
Developing machine X Omat 2000     Kodak, USA 
Electrophoresis chambers      Bio-Rad, USA 
Electronic cell counter Casy®    Innovatis, Germany 
Fusion A153601 Reader      Packard Bioscience, USA 
GS-800™ Calibrated Densitometer    Bio-Rad, USA 
Leica AS MDW      Leica, Germany 
MiniSpin® plus      Eppendorf, Germany 
Nanodrop®        Peqlab, Germany 
Nitrocellulose membrane     Bio-Rad, USA 
Olympus BX51       Olympus, Germany 
Olympus CAMEDIA C-4040 Zoom  Digital Camera Olympus, Germany  
PCR-thermocycler       MJ Research, USA 
Quantity One 1-D Analysis Software   Bio-Rad, USA 
Radiographic film X-Omat LS    Sigma-Aldrich, USA  
Western Blot Chambers     Bio-Rad, USA 
Chromatography Paper 3MM Whatman® Whatman International Ltd. 
England    
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4.1.2. Reagents 
ALK1-siRNA (10 μM) Santa Cruz Biotechnology, 
USA 
10mM dNTP Nucleotide mix    Promega, USA 
10x PCR buffer II      Applied Biosystems, USA 
Acrylamide solution, Rotiphorese Gel 30    Roth, Germany 
Agarose        Invitrogen, USA 
APS        Promega, USA 
2-Mercaptoethanol      Sigma-Aldrich, USA 
BMP2        R&D Systems, USA 
BMP4        R&D Systems, USA 
Bromophenol blue      Sigma-Aldrich, USA 
CASY®cups       Innovatis, Germany 
CASY®ton       Innovatis, Germany 
CompleteTM Protease inhibitor     Roche, Germany 
DNA Ladder (100 bp, 1kb)      Promega, USA 
Dulbecco’s phosphate buffered saline  PAA Laboratories, Austria 
EDTA        Promega, USA 
EGTA        Sigma-Aldrich, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK  
Ethanol       Sigma-Aldrich, USA 
Ethidiumbromide 1% (10 mg/ml)    Roth, Germany 
FBS        Invitrogen, USA 
FCS        Invitrogen, USA 
Glycine        Roth, Germany 
LipofectamineTM 2000     Invitrogen, USA 
Methanol        Sigma-Aldrich, USA 
MgCl2 (50 mM)      Invitrogen, USA 
MgCl2 (25 mM)       Applied Biosystems, USA 
MuLV Reverse Transcriptase (5000 U, 50 U/μl)  Applied Biosystems, USA 
NP-40        Merck, Germany 
Milk powder, Blotting Grade     Roth, Germany 
Opti-MEM       Gibco BRL, Germany 
Platinum® SYBR ® Green qPCR SuperMix-UDG  Invitrogen, USA 
Material and Methods 
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Precision Plus Protein Standards     Bio-Rad, USA 
Quick StartTM Bradford Dye Reagent, 1x   Bio-Rad, USA 
Random Hexamers (50 μM)      Applied Biosystems, USA 
RNase inhibitor (2000 U, 20 U/ μl)    Applied Biosystems, USA 
Silencer® Negative siRNA control #1 (50 μM),  Ambion, Germany 
Smooth Muscle Cell Growth Media 2    PromoCell, Germany 
Sodium dodecyl sulphate     Promega, USA 
Sodium orthovanadate      Sigma-Aldrich, Germany 
SuperSignal® West Pico Chemiluminescent Substrate  Pierce Protein Research 
Products, USA 
SupplementMix PromoCell, Germany 
Rotiphorese® 10x TAE Buffer    Roth, Germany 
TEMED       Bio-Rad, USA 
TGF-β-1       R&D Systems, USA 
Tween 20        Sigma-Aldrich, USA 
Tris         Roth, Germany 
Trypsin-EDTA       Gibco BRL, Germany 
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4.2. Methods 
 
4.2.1. Cell culture 
4.2.1.1. Cells 
Human pulmonary artery smooth muscle cells (hPASMCs) were ordered from 
Cambrex, USA and PromoCell, Germany. 
4.2.1.2. Culturing 
Cells were seed on 75 cm2 flasks. They were cultured in a combination of Smooth 
Muscle Cell Growth Media 2 (PromoCell, Germany) and SupplementMix (PromoCell, 
Germany). At a confluency of about 80%, cells were harvested with Trypsin, seed into 
75 cm2 flasks for further culturing or for experiments in dishes, chamber slides, 6 well 
plates or 12 well plates. Cells were used at passage 6 or earlier. To use cells for 
analyzing after experiments, they were washed with 1x PBS and stored at -80 °C if not 
used immediately. 
4.2.1.3. Culturing conditions 
For cell culture and experiments under normoxic conditions, the cell culture incubator 
was kept at 5% CO2 and 37 °C. Hypoxic conditions were created in an airtight chamber. 
The chamber was kept at 5% CO2, 94% N2 and 1% O2. 
 
4.2.2. RNA isolation, cDNA-synthesis and quantitative real-time polymerase chain 
reaction (qRT-PCR) 
4.2.2.1. RNA isolation from cells 
RNA was purified by using RNeasy Mini Kit (Qiagen, Germany). Protocol from kit 
provider was followed. RNA concentration then was measured by a Nanodrop® 
spectrophotometer. For quantification 1.5 μl of the sample were measured at a 
wavelength of 260 nm. Samples then were stored at -80 °C. 
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4.2.2.2. cDNA-synthesis 
Reverse transcription polymerase chain reaction was used to synthesize cDNA from 
RNA.  
Probes of 10 μl were prepared by using an equal amount of RNA per probe. The volume 
of the probes was equalled by adding RNase free H2O. The RNA then was heated at 70 
°C for 15 minutes, spun down for a few seconds and put on ice afterwards. 
The reagents for reverse transcription then were added to the tube, mixed gently and 
processed with the program for reverse transcription. After the reverse transcription the 
cDNA was stored at -20 °C until qRT-PCR was performed. 
 
Table 4.1. Reverse transcription thermal profile 
Time Temperature 
10 min 20 °C 
75 min 43 °C 
5 min 99 °C 
cool 4 °C 
 
 
Table 4.2. Reverse transcription reagents 
Reagent Volume 
10x PCR buffer II (MgCl2 free) 2 μl 
MgCl2 (25mM) 4 μl 
10mM dNTP mix 1 μl 
Random Hexamers (50 μM) 1.5 μl 
RNase Inhibitor ( 20 U/μl) 0.5 μl 
MuLV Reverse Transcriptase (50 U/μl) 1 μl 
 
 
4.2.2.3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
SYBR® Green I was used for quantification of DNA. This dye binds to the double-
stranded DNA and emits a signal. 
A 96 well plate was used. First the reagents components without the template were 
mixed and pipetted into the wells. The cDNA was added at last. For each experiment a 
negative control was run to detect possible contamination. 45 cycles were performed. 
PBGD (porphobilinogen deaminase) was used as a housekeeping gene.  It is described 
as universally expressed and as free of pseudogenes (Finke, Fritzen et al. 1993). It also 
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has been proved as a reference gene in related studies with hPASMCs (Schermuly, 
Stasch et al. 2008; Kwapiszewska, Markart et al. 2012). 
 
Table 4.3. qRT-PCR reaction mix 
Reagent Volume (μl) 
cDNA template 1 
MgCl2 (50mM) 1 
Forward primer (10μM) 0.5 
Reverse primer (10μM) 0.5 
Platinum® SYBR ® Green 
qPCR SuperMix-UDG 
13 
H2O (autoclaved) up to 25 μl total 
volume 
 
 
Table 4.4. qRT-PCR thermal cycling profile 
Step Time Temperature °C 
Activation of polymerase enzyme 2 min 50 
First Denaturation 5 min 95 
Second Denaturation 5 sec 95 
Annealing 5 sec 59 
Elongation 30 sec 72 
Dissociation step 1 15 sec 95 
Dissociation step 2 1 min 60 
Dissociation step 3 15 sec 95 
Dissociation step 4 15 sec 60 
 
 
4.2.2.4. Calculation of transcript amounts and differences in transcription 
The difference in target-gene transcription compared to reference-gene transcription is 
displayed as ∆CT-value and shows the relative transcript amount: 
∆CT: CT (reference) - CT (target) 
∆∆CT displays the difference in relative transcript levels (treated samples compared to 
control samples): 
∆∆CT:  ∆CT (treated) - ∆CT (control)            (Königshoff 2009)      
For interpretation of the data this means that positive ∆CT-values correlate with a higher 
expression of the target-mRNA compared to the reference-mRNA and that positive 
∆∆CT-values correlate with an upregulation of the mRNA of the corresponding treated 
sample compared to the mRNA of the control sample, while a negative ∆∆CT-value 
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corresponds to a downregulation of the mRNA of the corresponding treated sample 
compared to the mRNA of the control sample. 
 
Table 4.5. Human primers for qRT-PCR 
Gene Forward primer 
from 5´ to 3´ 
Reverse primer 
from 5´ to 3´ 
ALK1 GTGGAGTGTGTGGGAAAAG
G 
TCATGTCTGAGGCGATGA
AG 
ALK2 GTACAATGGTAGATGGAGT
GATGA 
CGTCAAATCTTCCTTCTTG
ACACT 
ALK3 TACACAGGAAACATTACAA CTTTTAGTGATTCTCCAAC 
ALK4 GTGGTTACTATGGCGGAGT
CG 
GTGGTTACTATGGCGGAG
TCG 
ALK5 CAGCTCTGGTTGGTGTCAG
A 
ATGTGAAGATGGGCAAG
ACC 
ALK6 CAAGAAAGAGGATGGTGA
G 
ATAATCATAAAGGGAACC
A 
BMPRII GAAGACTGTTGGGACCAGG
A 
TTGCGTTCATTCTGCATA
GC 
ENDOGLIN ACGCTCCCTCTGGCTGTTG GAAGGATGCCACAATGCT
G 
ID1 GTGGTGCGCTGTCGTCTGA AGTAACAGCCGTTATGTC
G 
ID2 CTGACCACCCTCAACACG CAGTGCTTTGCTGTCATTT
G 
Ki67 GCGGGCCGGATCGT GTCGACCCCGCTCCTTTT 
PAI-1 ATGCAGATGTCTCCAGCCC
TC 
GATGAAGGCGTCTTTCCC
CAG 
PBGD CCCACGCGAATCACTCTCA
T 
TGTCTGGTAACGGCAATG
CG 
PGK GACGTTAAAGGGAAGCGG
GT 
GAATTTGATGCTTGGGAC
AGC 
SMAD1 CAGTCTGTGAACCATGGAT
TTG 
TAACATCCTGGCGGTGGT
AT 
SMAD2 GGGAGGTTCGATACAAGAG
GCT 
GGACCACACACAATGCTA
TGACA 
SMAD3 AGCCATGTCGTCCATCCTG CTTCTTCCTTGACAACAA
TGGG 
SMAD4 TCACAATGAGCTTGCATTC
C 
GGGTCCACGTATCCATCA
AC 
SMAD5 TTACCCGTCCCCGATTTGA
AGAAC 
GCATTATGAAACAGAAGA
TATGGGG 
SMAD8 GGCCTCTTATGCACTCCAC
C 
GGAAATGCAGCTTAAGAC
ATGAC 
TGF-βRII TTTTCCACCTGTGACAACC
A 
GGAGAAGCAGCATCTTCC
AG 
Material and Methods 
                                                                                                                                          21 
 
4.2.2.5. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to visualize the qRT-PCR product. Gels were 
prepared and the product (mixed with loading-dye) was added into the wells. The size 
of the product could be determined by the DNA ladder which was added each run. A 
picture of the gel was taken by a camera under ultraviolet illumination. Gels were run at 
100 V. Gel percentage varied according to the molecular weight of the product. As 
running buffer 1x TAE was used. 
 
Table 4.6. Agarose gel mix 
Agarose 
1x EDTA buffer  
(40 mM Tris-acetate pH 8.0, 1 mM EDTA pH 8,0)   
0.5 μg/ml ethidium bromide 
(added after heating the other components) 
 
 
Table 4.7. Agarose gel electrophoresis loading buffer 
0,01% bromophenol blue 
40% glycerol 
1x TAE buffer 
 
 
4.2.3. Western Blot analysis 
4.2.3.1. Protein isolation from cells 
Cells were kept on ice during the whole process. Lysis buffer was used to collect the 
samples. Just before adding the lysis buffer to the cells, it was mixed with Complete 
(dilution 1:25, final concentration in buffer 10 μM) and Na3VO4 (dilution 1:100, final 
concentration in buffer 10 μM). The scraped cells were homogenised with syringe and 
needle by being pushed through for a few times and kept on ice for 30 minutes. During 
this time samples were vortexed every 5 minutes. After 30 minutes on ice samples were 
centrifuged for 15 minutes at 4 °C at 15000x g. Supernatant was kept and stored at  
-20 °C. 
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Table 4.8. Cell lysis buffer 
20 mM Tris 
150 mM NaCl 
1 mM EGTA 
1 mM EDTA 
0.5% NP-40  
 
 
Protein concentration was measured by a Fusion Plate Reader. Protein measurements 
were performed by Quick Start™ Bradford Assay (Bio-Rad, USA) and a Fusion 
Reader. 96 well plates were filled with 200 μl of Bradford dye. 10 μl protein was added. 
Six dilutions of bovine albumin serum (0.05 - 0.5 μg/μl) were used for protein standard 
curve. Samples were kept at room temperature for 15 minutes before measurements 
were performed. The plate reader was set at a wavelength of 570 nm to detect the 
optical density values of the solution. As a negative control blank lysis buffer and 
Bradford dye were run with each measurement. 
 
4.2.3.2. SDS poly-acrylamide gel electrophoresis 
Gels were prepared by first pouring the resolving gel mixture between two glass plates 
with about 1.5 mm space in between them. To avoid bubbles between the two gel 
layers, 1 ml of water was carefully put on top of the first layer. After polymerizing, the 
water was removed and the stacking gel solution was added on top. Just after pouring 
the second layer, a comb forming the wells for the proteins was carefully placed in the 
stacking gel. Gel was ready to use after polymerizing. Ratio between stacking gel and 
resolving gel was about 1/3 to 2/3. 
Depending on protein concentration and volume of the wells, an equal amount of 
protein was mixed with 2x loading buffer and heated at 95 °C for 10 minutes for 
denaturation. Proteins were loaded to the gel and run at 120 V in SDS running buffer. 
To determine the size of the protein, a marker was run with each experiment.  
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Table 4.9. Loading buffer 
Tris-HCL (125 mM, pH 6,8) 
SDS (4%) 
Bromphenol blue (0.025%) 
Glycerol (20%) 
2-mercaptoethanol (10%) 
 
 
Table 4.10. SDS poly-acrylamide gel 
Reagent 
Volume 
Resolving gel (10%) Stacking gel (5%) 
dH2O 3.98 ml 3.4 ml 
Acrylamide 30% 3.325 ml 0.83 ml 
Tris-HCL (1.5 M, pH 8.8) 2.5 ml - 
Tris-HCL (1 M, pH 6.8) - 0.63 ml 
SDS (10%) 100 μl 50 μl 
APS (10%) 100 μl 50 μl 
TEMED 4 μl 5 μl 
 
 
Table 4.11. Running buffer  
Reagent Volume (for 10x) 
Tris (25 mM, pH 8.3) 30 g 
Glycin (0.2 M) 144 g 
SDS (10%) 100 ml 
dH2O up to 1000 ml 
 
 
4.2.3.3. Protein Transfer 
For transfer two sponges, two pieces of filter paper and a piece of nitrocellulose 
membrane were soaked in transfer buffer. In a sandwich clamp from the black side to 
the white side a sponge, one piece of filter paper, the gel, the membrane, a filter paper 
and another sponge were arranged. To avoid bubbles it was rolled with a roll over the 
sandwich before closing the sandwich box. Protein transfer was performed at 120 V for 
60 minutes in transfer buffer. An ice container was put in the chamber to reduce heat 
development.  
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Table 4.12. Transfer buffer  
Reagent  Volume 
Tris base (25 mM) 3.02 g 
Glycin (192 mM) 14.4 g 
Methanol (20%) 200 ml 
dH2O up to 1000 ml 
 
 
4.2.3.4. Protein detection 
The nitrocellulose membrane was washed in washing buffer for 3 minutes after the 
protein transfer. Afterwards the membrane was blocked with 5% blocking buffer for 60 
minutes at room temperature. After blocking the membrane was transferred to blotting 
buffer containing diluted primary antibodies to allow the primary antibody to bind. This 
process was performed for 60 minutes at room temperature or overnight at 4 °C.  
Dilution of the antibody depended on the antibody used.  
After incubating the first antibody, the membrane was washed in washing buffer 3x for 
10 minutes. Buffer containing HRP-conjugated secondary antibodies was prepared. 
Secondary antibodies from the same specimen as the first antibody were diluted with 
blocking buffer. Incubation time was 60 minutes at room temperature. 
Chemiluminescence was used to detect protein bands. 
The blots could be incubated with a different antibody. Blots were stripped in stripping 
buffer at 52 °C for 10 minutes. Just before using the stripping buffer, 3.47 ml of 2-
mercaptoethanol were added to 50 ml of stripping buffer. After stripping the membranes 
were rinsed in washing buffer.  
 
Table 4.13. Washing buffer 
Reagent Volume 
Tween-20 1 ml 
1xPBS up to 1000 ml 
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Table 4.14. Blocking buffer 
Reagent Volume 
Tween-20 1 ml 
Non-fat dry milk powder 50 g 
1xPBS up to 1000 ml 
 
 
Table 4.15. Stripping buffer  
Reagent Volume 
Tris-HCl (1M, pH 6.8) 31 ml 
SDS (10%) 10 ml 
dH2O Up to 500ml 
 
 
4.2.3.5. Densitometry 
Densitometric analysis was performed to correct the factor of differences in protein 
loading amount. With the use of a GS-800™ Calibrated Densitometer and Quantity One 
1-D Analysis Software optical density was measured and the expression of the protein 
of interest was normalized to Cdk4, which was used as a loading control. The results are 
displayed as ratio of optical density: optical density of protein of interest/ optical density 
of Cdk4. 
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Table 4.16. Primary antibodies 
Antibody Source 
Molecular 
weight 
of protein 
Dilution  
Western 
Immunoblot 
Dilution 
ICCH Company 
ALK1  goat 53 kDa 1:1000 1:200 
Santa Cruz 
Biotechnology, 
USA 
ALK1  rabbit 53 kDa 1:1000 1:200 
Santa Cruz 
Biotechnology, 
USA 
ALK1 mouse 53 kDa 1:1000 1:200 R&D Systems, USA 
ALK5/ 
TGF-βRI  rabbit 53 kDa 1:1000  
Santa Cruz 
Biotechnology, 
USA 
Cdk4 rabbit 34 kDa 1:2000  
Santa Cruz 
Biotechnology, 
USA 
ID1 rabbit 15 kDa 1:1000  
Santa Cruz 
Biotechnology, 
USA 
ID2 rabbit 15 kDa 1:1000  
Santa Cruz 
Biotechnology, 
USA 
Phospho-
Smad1/5/8 rabbit 60 kDa 1:1000  
Cell Signaling 
Technology®, 
USA 
Smad1 mouse 52/56 kDa 1:1000  
Santa Cruz 
Biotechnology, 
USA 
Phospho-
Smad2  rabbit 60 kDa 1:1000  
Santa Cruz 
Biotechnology, 
USA 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
                                                                                                                                          27 
 
Table 4.17. Secondary antibodies  
Antibody Source 
Dilution 
Western 
Immunoblot 
Dilution 
ICCH Company 
anti-mouse IgG (HRP-
conjugated) goat 1:3000  
Pierce Protein 
Research Products, 
USA 
anti-rabbit IgG (HRP-
conjugated) goat 1:3000  
Pierce Protein 
Research Products, 
USA 
anti-goat IgG (HRP-
conjugated) rabbit 1:3000  
Pierce Protein 
Research Products, 
USA 
anti-mouse IgG 
(ZyMaxTM )  (FITC-
conjugated) 
goat  1:300 ZYMED
®  
Laboratories, USA 
anti-rabbit IgG 
(ZyMaxTM ) (FITC-
conjugated) 
goat  1:300 ZYMED
® 
Laboratories, USA 
 
 
4.2.4. Immunofluorescence 
Eight-well chamber slides were used. Cells were washed with 4 °C 1x PBS twice. PBS 
was removed. 400 μl cold Methanol 100% was added to each chamber and cells were 
placed at -20 °C for 5 minutes. Afterwards slides were washed in 1x PBS twice and 
incubation with 400 μl/ well blocking buffer (5% FCS in 1x PBS) took place for 60 
minutes at room temperature. Blocking buffer was removed and the solution containing 
primary antibody was added. Incubation with primary antibody was performed at room 
temperature for 60 minutes (300 μl/ well) or overnight at 4°C (400 μl antibody solution/ 
well). Slides were washed 3x for 10 minutes with 1x PBS, then solution containing 
fluorescein-5-isothiocyanate-labeled secondary antibody was added (300 μl/ well). This 
solution consisted of diluted secondary antibody (1:200) in 2.5% FBS. Cells were 
incubated for 60 minutes at room temperature. From this step on light was avoided by 
covering the slides. After incubation, slides were washed 5x for 5 minutes in 1x PBS. A 
mounting medium containing DAPI (4`, 6-diamidino-2-phenylindole) was added (100 
μl/ slide) and slides were covered with coverslips. Cells were detected by a fluorescence 
microscope. 
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4.2.5. Short interfering RNA (siRNA) transfection 
Experiments were performed on six well plates with cells being 60-80% confluent. 16 
hours prior to transfection cells were starved with 0.1% media. For transfection the cells 
were covered with normal growth medium and supplement mix. Cells were transfected 
with 50 nM ALK1 siRNA or 50 nM Silencer® Negative siRNA control #1. Transfection 
solutions were prepared as following.  
Opti-MEM and LipofectamineTM 2000 were mixed and incubated for 15 minutes. After 
10 minutes Opti-MEM and the siRNA were mixed and incubated for 5 minutes. When 
15 minutes in total had passed, the solutions were combined, incubated for 15 minutes 
and added to the cells. Cells were incubated for 4 hours, then normal growth media and 
supplement mix was added. Cells were let for 24 hours. 
 
4.2.5.1. Calculation for siRNA remaining expression/ knockdown 
siRNA knockdown was calculated by qRT-PCR using the comparative CT  method 
(∆∆CT). Data are normalized (∆CT) by using a control transcript (here PBGD).  
∆CT (sample): CT (control transcript) - CT (gene of interest) 
∆CT (negative control): CT (negative control transcript) - CT (negative control gene of interest) 
∆CT for the gene of interest is compared to the ∆CT of the negative control siRNA 
treated sample. 
∆∆CT = ∆CT (sample) - ∆CT (negative control) 
Percent remaining gene expression and percent knockdown are calculated as following. 
Remaining expression= 2∆∆CT; knockdown= 1 - 2∆∆CT; values were then converted in 
percent (adapted from Ambion TechNotes Newsletter, 2007) 
 
4.2.6. Stimulation of hPASMCs with TGF-β1, BMP2 and BMP4 
hPASMCs were stimulated with TGF-β1, BMP2 and BMP4. Cells were starved with 
0.5% growth media for 4 hours. Then 5% growth media was added and the cells were 
stimulated with TGF-β1 (2 ng TGF-β1/ ml growth medium), BMP2 (10 ng BMP2/ ml 
growth medium) or BMP4 (10 ng BMP4/ ml growth medium). 
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4.2.7. Cell count 
Cells were carefully harvested. 5 ml of CASY®ton were filled in a CASY®cup and 50 μl 
of the cell solution were added. The CASY®cup was shaken once, put in and counted by 
the electronic cell counter CASY®. 
 
4.2.8. Wound scratch assay 
hPASMCs were cultured until about 80% confluent. Then a “wound” with a pipette tip 
was created from one end of the plate to the other. Transfection and stimulation were 
performed as described previously. Migration was kept hold and made comparable by 
taking photographs at defined points in time. 
 
4.2.9. Statistics 
Data derived from qRT-PCR was analysed either by one-way ANOVA followed by a 
Dunnetts post-hoc test or with a two tailed one sample t-test. The ANOVA with 
Dunnetts post-hoc test was used comparing the values from hPASMCs exposed to 
hypoxia compared to the normoxic control value. The two-tailed one sample t-test was 
used on the comparison of transfection of hPASMCs with ALK1 siRNA versus 
negative siRNA. 
Ratios of optical density obtained from Western Blots were analysed by a two tailed one 
sample t-test with bonferroni correction for multiple comparisons. 
The cell count experiment was analysed via two-way ANOVA and corrected for 
multiple comparisons with bonferroni correction. 
Number of n is indicated in the description of each experiment in chapter “Results”. If 
number of n≤ 2, no statistical analysis regarding p-value was performed. p-values< 0.05 
were regarded as statistically significant. Values are presented as mean ± s.e.m. 
(Statistical analysis was performed with advice of Dr. Jochen Wilhelm).
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5. Results 
5.1. Expression analysis of members of the TGF-β system in hPASMCs 
under hypoxia  
 
5.1.1. Expression analysis by quantitative RT-PCR 
For expression analysis of different members of the TGF-β system in hPASMCs, cells 
were exposed to hypoxia for 6, 24 and 48 hours. A normoxic control was measured at 
24 hours after starting the experiment. mRNA was isolated and qRT-PCR was 
performed. PBGD was used as housekeeping gene (compare chapter 4.2.2.3.). 
5.1.1.1. Induction of hypoxia 
Phosphoglycerate kinase (PGK) is inducible upon hypoxia (Park, Haase et al. 2007). 
PGK was used to demonstrate the exposure to hypoxia, as a positive control. Compared 
to the normoxic control, PGK was upregulated significantly after 24 and 48 hours 
exposure to hypoxia (∆∆CT of 0.81± 0.19, p= 0.03 and ∆∆CT of 1.09 ± 0.2, p= 0.01, 
respectively) (figure 5.1.). 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Expression analysis of PGK in hPASMCs as positive control for 
exposure to hypoxia by qRT-PCR. mRNA expression analysis was performed in 
hPASMCs exposed to hypoxia for 6, 24 and 48 hours and compared to a normoxic 
control. n= 5. Results are displayed as ∆∆CT-values and are presented as mean ± s.e.m., 
* p< 0.05 vs. normoxic control.  
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5.1.1.2. TGF-β/ BMP receptors  
Receptor expression level in hPASMCs was investigated after exposing the cells to 6, 
24 and 48 hours of hypoxia. A normoxic control as described above was run with each 
experiment. Of the TGF-β/ BMP receptors ALK1 - ALK6 as well as TGF-βRII, 
BMPRII and Endoglin were investigated. Of the investigated receptors, ALK1 was 
significantly upregulated after 24 and 48 hours exposure to hypoxia compared to the 
normoxic control (∆∆CT of 1.07 ± 0.28, p= 0.04 and ∆∆CT of 1.26 ± 0.28, p= 0.02, 
respectively). ALK5 was significantly upregulated after 48 hours exposure to hypoxia 
compared to the normoxic control (∆∆CT of 0.76 ± 0.28, p= 0.04). All other receptors 
showed the tendency of upregulation upon exposure to hypoxia for 48 hours compared 
to the normoxic control, but for these results statistical significance could not be shown 
(figure 5.2. and figure 5.3.). 
5.1.1.3. Smads 
To investigate potential changes in the downstream mediators of the TGF-β family, 
Smad expression levels were investigated. Therefore Smad1 - Smad5 and Smad8 were 
studied. hPASMCs were exposed to hypoxia for 6, 24 and 48 hours and mRNA 
expression was analysed by qRT-PCR. Of the investigated genes Smad1 showed a 
significant downregulation after 6 hours of hypoxia compared to the normoxic control 
(∆∆CT of -0.98 ± 0.18, p= 0.01). All Smads investigated but Smad1 showed the 
tendency of increased expression after 48 hours exposure to hypoxia compared to the 
normoxic control, as well as the tendency of decreased expression after 6 hours 
exposure to hypoxia, but these results were not statistically significant (figure 5.4.). 
5.1.1.4. ALK1 and ALK5 target genes 
To further investigate the signalling pathway mediated by ALK1 and ALK5, their target 
gene expressions were analysed, ID1 and ID2 for ALK1 and PAI-1 for ALK5. Of the 
target genes investigated ID2 showed a significant upregulation after 48 hours exposure 
to hypoxia compared to the normoxic control (∆∆CT of 1.27 ± 0.27, p= 0.04). ID1 and 
PAI-1 showed a general tendency of upregulation upon exposure to hypoxia without 
statistical significance (figure 5.5.). 
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Figure 5.2. Expression analysis of ALK1 - ALK6 in hPASMCs exposed to hypoxia  
by qRT-PCR. mRNA expression analysis was performed in hPASMCs exposed to 
hypoxia for 6, 24 and 48 hours and compared to a normoxic control. ALK1 and ALK5 
n= 5; ALK3 and ALK4 n= 3; ALK2 and ALK6 n= 2. Results are displayed as ∆∆CT-
values and are presented as mean ± s.e.m., * p< 0.05 vs. normoxic control. 
 
 
 
 
Figure 5.3. Expression analysis of TGF-βRII, BMPRII and Endoglin in hPASMCs 
exposed to hypoxia by qRT-PCR. mRNA expression analysis was performed in 
hPASMCs exposed to hypoxia for 6, 24 and 48 hours and compared to a normoxic 
control. TGF-βRII and BMPRII n= 4; Endoglin n= 3. Results are displayed as ∆∆CT-
values and are presented as mean ± s.e.m., no statistical significance (p< 0.05 vs. 
normoxic control) could be detected. 
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Figure 5.4. Expression analysis of Smad1 – Smad5 and Smad8 in hPASMCs 
exposed to hypoxia by qRT-PCR. mRNA expression analysis was performed in 
hPASMCs exposed to hypoxia for 6, 24 and 48 hours and compared to a normoxic 
control. Smad1 n= 5; Smad2 n= 2; Smad3, Smad5 and Smad8 n= 3; Smad4 n= 4. 
Results are displayed as ∆∆CT-values and are presented as mean ± s.e.m., * p< 0.05 vs. 
normoxic control. 
 
 
 
Figure 5.5. Expression analysis of the ALK1 and ALK5 target genes ID1/ ID2 and 
PAI-1 respectively in hPASMCs exposed to hypoxia by qRT-PCR. mRNA 
expression analysis was performed in hPASMCs exposed to hypoxia for 6, 24 and 48 
hours and compared to a normoxic control. ID1 n= 5; ID2 n= 4; PAI-1 n= 3. Results 
are displayed as ∆∆CT-values and are presented as mean ± s.e.m., * p< 0.05 vs. 
normoxic control. 
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5.1.2. Expression analysis by Western Blotting 
To profile the protein expression of the respective proteins under normoxic and hypoxic 
conditions hPASMCs were exposed to hypoxia for 48 hours and compared to normoxia. 
Proteins were isolated and SDS-PAGE Western Blotting was performed. First the 
protein expression levels of the TGF-β/ BMP receptors ALK1 and ALK5 were 
investigated. To detect potential changes in normoxia versus hypoxia exposed 
hPASMCs regarding downstream mediators the protein expression level of Smad1 was 
investigated. In the next step the phosphorylated form of the ALK1 and ALK5 
downstream mediators Smad1/ Smad5/ Smad8 and Smad2 respectively were studied, 
followed by the ALK1 target genes ID1 and ID2. 
To objectify the results, densitometry was performed. On protein level no significant 
changes in expression were detected for the proteins investigated. Cdk4 was used as a 
loading control (figure 5.6. - 5.13.).  
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Figure 5.6. Expression analysis of ALK1 and ALK5 in hPASMCs exposed to 
hypoxia by Western Blotting. hPASMCs were exposed to normoxia (N) or hypoxia 
(H) for 48 hours. Cdk4 was used as a loading control. n= 3. 
 
 
 
 
 
 
 
 
 
 
        
 
Figure 5.7. Expression analysis of ALK1 and ALK5 in hPASMCs exposed to 
hypoxia. Quantification by densitometry. n= 3. Results are displayed as ratio of 
optical density (optical density of protein of interest/ optical density of Cdk4) and are 
presented as mean ± s.e.m. No statistical significance (p< 0.05) for cells exposed to 
hypoxia vs. cells exposed to normoxia could be detected. 
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Figure 5.8. Expression analysis of Smad1 in hPASMCs exposed to hypoxia by 
Western Blotting. hPASMCs were exposed to normoxia (N) or hypoxia (H) for 48 
hours. Cdk4 was used as a loading control. n= 3. 
 
 
 
 
 
 
 
Figure 5.9. Expression analysis of Smad1 in hPASMCs exposed to hypoxia. 
Quantification by densitometry. n= 3. Results are displayed as ratio of optical density 
(optical density of protein of interest/ optical density of Cdk4) and are presented as 
mean ± s.e.m. No statistical significance (p< 0.05) for cells exposed to hypoxia vs. 
cells exposed to normoxia could be detected. 
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Figure 5.10. Expression analysis of Phospho-Smad1/ -Smad5/ -Smad8 and 
Phospho-Smad2 in hPASMCs exposed to hypoxia by Western Blotting. hPASMCs 
were exposed to normoxia (N) or hypoxia (H) for 48 hours. Cdk4 was used as a 
loading control. n= 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Expression analysis of Phospho-Smad1/ -Smad5/ -Smad8 and 
Phospho-Smad2 in hPASMCs exposed to hypoxia. Quantification by 
densitometry. n= 4. Results are displayed as ratio of optical density (optical density of 
protein of interest/ optical density of Cdk4) and are presented as mean ± s.e.m. No 
statistical significance (p< 0.05) for cells exposed to hypoxia vs. cells exposed to 
normoxia could be detected. 
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Figure 5.12. Expression analysis of the ALK1 target genes ID1/ ID2 by Western 
Blotting. hPASMCs were exposed to normoxia (N) or hypoxia (H) for 48 hours. Cdk4 
was used as a loading control. n= 4. 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Expression analysis of the ALK1 target genes ID1/ ID2.  
Quantification by densitometry. n= 4. Results are displayed as ratio of optical density 
(optical density of protein of interest/ optical density of Cdk4) and are presented as 
mean ± s.e.m. No statistical significance (p< 0.05) for cells exposed to hypoxia vs. 
cells exposed to normoxia could be detected. 
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5.2. Proliferation and migration 
 
As mentioned before, proliferation and migration of PASMCs play a key role in the 
development of PAH.  For animals it has been shown that smooth muscle like cells 
move in previously nonmuscularised vessels and that media thickening is caused by an 
accumulation of smooth muscle cells (Stenmark, Fagan et al. 2006). Furthermore 
different theories exist about ALK1 inhibiting or stimulating proliferation and 
migration. Hence it was interesting to look out for proliferation and migration with 
focus on ALK1 in the specific context of hPASMCs exposed to hypoxia. 
 
5.2.1. Proliferation analysis of hPASMCs 
5.2.1.1. Expression analysis of the proliferation marker Ki67 
To investigate the effect hypoxia plays on hPASMCs proliferation, cells exposed to 
hypoxia for 6, 24 and 48 hours were analysed for expression of the proliferation marker 
Ki67. A normoxic control was measured at 24 hours after starting the experiment. No 
significant upregulation or downregulation was observed upon exposure to hypoxia 
compared to the normoxic control (figure 5.14.). 
 
 
 
Figure 5.14. Expression analysis of the proliferation marker Ki67 in hPASMCs 
exposed to hypoxia by qRT-PCR. mRNA expression analysis was performed in 
hPASMCs exposed to hypoxia for 6, 24 and 48 hours and compared to a normoxic 
control. n= 3. Results are displayed as ∆∆CT-values and are presented as mean ± s.e.m., 
no statistical significance (p< 0.05 vs. normoxic control) could be detected. 
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5.2.1.2. siRNA knockdown of ALK1 in hPASMCs 
Results of the expression analysis on mRNA level of hPASMCs exposed to hypoxia 
showed a significant upregulation of ALK1 after 24 and 48 hours of exposure to 
hypoxia compared to normoxia. To further investigate the role ALK1 plays in migration 
and proliferation, siRNA knockdown of hPASMCs was performed. Efficiency of 
knockdown was shown on mRNA level by qRT-PCR. Percentage was calculated as 
described in chapter 4. ALK1 expression was successfully knocked down after 
transfection with siRNA for ALK1 (50 nm) compared to transfection with negative 
siRNA (∆∆CT of -1.93 ± 0.23, p= 0.02) (figure 5.15.). Knockdown obtained was 73.8%, 
the remaining gene expression was 26.2% (calculated as described in chapter 4.2.5.1.).   
 
 
 
Figure 5.15. ALK1 siRNA mediated knockdown in hPASMCs. hPASMCs were 
transfected with ALK1 siRNA and negative siRNA. mRNA was isolated and qRT-PCR 
was performed. n= 3. Results are displayed as ∆∆CT-value and presented as mean ± 
s.e.m., * p< 0.05. 
 
 
5.2.1.3. Cell count of siRNA transfected cells under normoxic and hypoxic conditions 
Next step was to investigate the influence of ALK1 knockdown on hPASMCs 
proliferation activity. Not transfected, negative siRNA and ALK1 siRNA transfected 
cells were exposed to normoxia and hypoxia. Cells were counted by the Electronic cell 
counter CASY®. Performed analysis aimed to detect possible influences of hypoxia 
versus normoxia and ALK1 siRNA transfection versus negative siRNA transfection. 
Additionally a set of not treated cells was run with the experiment. 
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Statistical significance could be detected for an increase of the not treated cells in the 
hypoxia group compared to the not treated cells in the normoxia group (p= 0.03). In the 
normoxia group a tendency of decrease in cell number was found in ALK1 siRNA 
transfected cells compared to the negative siRNA transfected cells (figure 5.16.).  
 
 
Figure 5.16. Proliferation assay of hPASMCs not transfected and transfected with 
ALK1 siRNA and negative siRNA and exposed to normoxia and hypoxia. Cells 
were counted by an electronic cell counter. Results were derived from 4 independent 
experiments and are presented as mean ± s.e.m. 
 
 
5.2.2. Migration analysis of hPASMCs by scratch wound assay 
Scratch wound assay was performed to detect potential changes in migration capacities 
of ALK1 siRNA transfected hPASMCs compared to the negative siRNA transfected 
hPASMCs. Also a set of not transfected cells was run with the experiment. Additionally 
the effect of stimulation with TGF-β1, BMP2 and BMP4 was investigated in order to 
identify a possible ligand that will activate the ALK1 receptor on the hPASMCs. 
hPASMCs were cultured and a scratch wound was performed. The migration activity 
was recorded by taking photographs. No clear visible influence of ALK1 knockdown or 
stimulation with TGF-β, BMP2 and BMP4 could be detected (figure 5.17.) 
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(A) 
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(B) 
 
 
 
 
 
Figure 5.17. Migration assay:  Scratch wound assay with ALK1 siRNA 
transfected hPASMCs unstimulated and stimulated with TGF-β1, BMP2 and 
BMP4. A. and B. each show an independent experiment. Photographs of cells for one 
experiment were taken at the same time but differ in between experiments because of 
differences in growth rate. Experiment was performed twice. 
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5.3. Localisation of ALK1 in hPASMCs under normoxic and hypoxic 
conditions by immunofluorescence 
 
Results obtained by previous experiments suggested an increase of ALK1 on mRNA 
level as well as a tendency for proliferation induced with hypoxia. To further clarify 
these results, ALK1 was localised in the hPASMCs by means of immunofluorescence. 
Cells were exposed to normoxic or hypoxic conditions for 24 hours. A specific staining 
of the membrane was obtained. No consistent results could be found concerning the 
ALK1 staining intensity or the proliferation of hPASMCs (figure 5.18.) 
 
 
 
Figure 5.18. Localisation of ALK1 in hPASMCs exposed to hypoxia by 
immunofluorescence. Cells were exposed to normoxia and hypoxia for 24 hours and 
stained afterwards. As secondary antibody a FITC-conjugated antibody was used. Two 
independent experiments were performed. m= magnification. 
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6. Discussion 
6.1. Overview 
 
6.1.1. Pulmonary hypertension 
Pulmonary hypertension is a serious condition. Although treatment possibilities exist, 
most patients eventually die from the disease (Morrell, Adnot et al. 2009). All age 
groups, from neonate to adult, can be affected by PAH (Rabinovitch 2008). In PAH the 
lumen of the artery decreases while resistance increases. This leads to right heart failure 
(Humbert, Morrell et al. 2004). As previously described, causes of pulmonary 
hypertension are manifold.  
 
6.1.2. Background and aims  
For this thesis the linkage between HHT patients with ALK1 mutations who develop 
PH (chapter 2; Harrison, Flanagan et al. 2003) and the implication of ALK1 being a 
causal factor of hereditary and associated forms of PAH  (Machado, Eickelberg et al. 
2009 and references therein) play an important role. Furthermore the results of a study 
stating ALK1 being downregulated in IPAH patients lung homogenates compared to 
donor lungs homogenates as well as in mice exposed to hypoxia lung homogenates 
compared to normoxic control mice homogenates  (Amarie 2009) strongly influenced 
the performed study.  
In particular this thesis focuses on TGF-β pathway components expression profiling in 
hPASMCs exposed to hypoxia and compared to normoxia control. Special attention was 
given to the role of ALK1 in hPASMCs. 
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6.2. Hypoxia and pulmonary hypertension 
 
6.2.1. Hypoxia models 
Hypoxia can be regarded as a cause for pulmonary vascular remodelling and cell 
proliferation. The hypoxic stimulus in high altitudes leads to pulmonary hypertension as 
well as hypoxic lung conditions at sea level. Hypoxia is considered as a more 
physiological stimulus than monocrotaline, another model used to induce pulmonary 
hypertension and study vascular remodelling (Pak, Aldashev et al. 2007). 
Monocrotaline induced PH does usually not lead to typical plexiform lesions, but is also 
used as a standard model for studying PH (Dorfmuller, Perros et al. 2003). For rats it 
has been shown that hypoxia- and monocrotaline induced pulmonary vascular 
remodelling is heterogeneous not only between the groups of treatment but also in 
different parts of pulmonary artery vasculature (van Suylen, Smits et al. 1998). Thus, 
when comparing results derived from PH related models, it has to be taken into 
consideration that different models might influence the results, especially under the 
aspect that other, less common models exist (Pak, Aldashev et al. 2007). 
To make sure that in the experiments performed the hPASMCs were exposed to 
hypoxia, oxygen content of the chambers was measured constantly by a sensor. To 
show the influence of hypoxia on the cells, PGK expression in the cells was measured 
by qRT-PCR, as PGK is inducible with hypoxia (Park, Haase et al. 2007). Experiments 
performed show a significant increase on PGK mRNA level after 24 and 48 hours of 
exposure to hypoxia compared to normoxic control, indicating the exposure to hypoxia. 
 
6.2.2. Proliferation of hPASMCs under hypoxia  
For animals that develop chronic hypoxia induced PH some almost general features of 
pulmonary arteries are known. Concerning smooth muscle cells it has been revealed that 
smooth muscle like cells emerge in previously nonmuscularised vessels and furthermore 
that the media thickening is – among other changes - caused by hypertrophy and an 
enhanced accumulation of smooth muscle cells (Stenmark, Fagan et al. 2006). 
For PASMCs in vitro experiments universal behaviour concerning proliferation of cells 
exposed to hypoxia cannot be made. Pak et al. summarize the effect of acute hypoxia on 
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PASMC proliferation in vitro as following: Evidence has been found that influence of 
acute hypoxia on proliferation is very heterogeneous. Studies show that acute hypoxia 
indeed is a stimulator for PASMC proliferation, but contradictory studies have been 
performed, ranging from the outcome that acute hypoxia has no direct effect on 
proliferation of PASMCs to the result that PASMCs even decrease under acute hypoxic 
conditions. As potential reasons for these differences Pak et al. list differences in 
sources of cells, seeding density, grade of hypoxia, serum concentration used for 
stimulation and phenotypic variations of cells (Pak, Aldashev et al. 2007). 
In the cell count experiment performed, the group of not transfected hPASMCs exposed 
to hypoxia showed a significant increase in cell number compared to the group of 
hPASMCs exposed to normoxia. Experiment was performed under 1% O2 and cells 
were exposed for 24 hours. In contrast analysis of the proliferation marker Ki67 on 
mRNA level from hPASMCs exposed to hypoxia did not reveal a significant 
upregulation. Experiment also was performed under 1% O2 and cells were exposed for 
6, 24 and 48 hours. For both experiments culturing conditions were the same, but age of 
cells and seeding density vary between the experiments. It is not clear if these 
differences in conditions might be enough to lead to these diverging results or if other, 
unknown factors contribute to the outcome of the experiment.    
Other studies performed on pulmonary smooth muscle cells exposed to hypoxia 
revealed a wide range of different results. Stotz et al. displayed data using rat 
pulmonary microvascular smooth muscle cells (PMVSMCs) representing a trend of 
proliferation of cells exposed to hypoxia with 1% O2 compared to a normoxic control 
group, assessed by [3H]thymidine incorporation (Stotz, Li et al. 2004). In contrast to 
this data Rose, Grimminger et al. show a trend of decrease of proliferation on 
experiments performed with hPASMCs exposed to hypoxia with 1% O2 compared to a 
normoxic control group measured by BrdU incorporation. (Rose, Grimminger et al. 
2002). Cooper and Beasley observed a significant proliferation of hPASMCs when 
comparing hPASMCs exposed to hypoxia with 5% O2 compared to hPASMCs exposed 
to 20% O2.  (Cooper and Beasley 1999).  
Adding to the points previously described that influence results in proliferation 
experiments also the length of exposure to hypoxia might contribute to the wide range 
of results. 
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6.3. TGF-β signalling and pulmonary hypertension 
6.3.1. ALK1  
ALK1 is linked to pulmonary hypertension via HHT. Patients which suffer from HHT 
occasionally also suffer from PH. Association between HHT and PH mostly occurs in 
patients with ALK1 signalling defects (Harrison, Flanagan et al. 2003). Varying 
mutations have been found in different segments of the gene coding for ALK1. It has 
been suggested that ALK1 mutations are liable for opposite effects on vasculature: on 
one hand ALK1 mutations lead to occluded arteries while at the same time ALK1 
mutations lead to vascular dilatation (Trembath, Thomson et al. 2001). 
 
Investigations of whole lung mRNA from lung homogenate of mice with hypoxia 
induced pulmonary hypertension show a decrease of ALK1 on mRNA- and protein 
level compared to a control group. In mRNA isolated from patients lung samples 
suffering from IPAH ALK1 was downregulated compared to donor lungs (Amarie 
2009).  
Interestingly in hPASMCs exposed to hypoxia for 24 and 48 hours ALK1 was 
significantly upregulated on mRNA level compared to the normoxic control group. In 
hPASMCs exposed to hypoxia for 24 hours and investigated by means of 
immunofluorescence no constant changes could be detected regarding staining intensity 
of ALK1 compared to normoxic control staining. 
Investigations showed ALK1 being mainly expressed in ECs and at sites of 
angiogenesis (Goumans, Lebrin et al. 2003). Possibly the proportion of ALK1 in 
hPASMCs is too small to influence the mRNA expression of whole lung homogenates 
and thus the different results. 
For endothelial cells it is suggested that the activation state of the endothelium depends 
on the activation of ALK1 and ALK5. TGF-β signals either through ALK1/ Smad1 and 
Smad5 which leads to enhanced migration and proliferation or through ALK5/ Smad2 
which inhibits migration and proliferation (Goumans, Valdimarsdottir et al. 2002).  
The proliferation experiment run on hPASMCs transfected with ALK1 siRNA or 
negative siRNA and exposed to hypoxia and normoxia for 24 hours revealed partly 
results in consent compared to the situation described with ECs. In the normoxic group 
number of cells transfected with ALK1 siRNA showed a tendency to decrease 
compared to the negative siRNA transfected cells. In the hypoxia group the cell count 
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did not show such a tendency, which might point to a possible influence of hypoxia. 
From result constellation in this experiment it has to be taken into consideration that 
cells might be influenced or shocked by transfection procedure and therefore the results 
might be questionable.   To show that transfection procedure was successful, percentage 
of ALK1 knockdown was quantified by qRT-PCR run on transfected hPASMCs. 
Knockdown obtained was about 74%.  
Migration of hPASMCs was investigated by wound scratch assay. No altered migration 
was seen with siRNA ALK1 versus negative siRNA transfected cells. Also stimulation 
with TGF-β1, BMP2 and BMP4 did not display any changes. Nevertheless, when 
evaluating these experiments it has to be reminded the fact that due to contamination 
etc. only two of the performed wound scratch assays experiments could be taken into 
consideration.   
In literature different explanatory approaches were made regarding the topic of 
migration. For TGF-β1 stimulation of EC it was demonstrated that high doses of TGF-
β1 inhibit migration of EC while lower doses of TGF-β1 increase migration (Pepper, 
Vassalli et al. 1993; Goumans, Valdimarsdottir et al. 2002). In contrast to Goumans, 
Valdimarsdottir et al., Lamouille, Mallet et al. gave rise to the idea that ALK1 leads to 
inhibition of migration and proliferation of endothelial cells. An adenoviral expression 
of a constitutively active form of ALK1 was used to investigate different kinds of 
endothelial cells regarding migration. For human microvascular endothelial cells from 
the dermis (HMVEC-d´s), human microvascular endothelial cells (HMEC-1´s), 
HMVECs from the lung and human umbilical vein endothelial cells (HUVECs) infected 
an inhibited migration was shown as assessed by wound assay compared to a control 
group. On top of that for constitutively active ALK1 infected HMVEC-d´s an inhibited 
proliferation was shown. The author explains that for the first time in this study it could 
be shown that ALK1 activation leads to Smad1/ Smad5 phosphorylation which here 
results in inhibited migration and proliferation  (Lamouille, Mallet et al. 2002). 
Furthermore it was shown that as a ligand of ALK1 BMP9 inhibits migration and 
proliferation of ECs (Scharpfenecker, van Dinther et al. 2007) and in another study it 
was also demonstrated that BMP9 and BMP10 inhibit migration of ECs (David, Mallet 
et al. 2007).  For Goumans these discoveries lead to the assumption that ALK1 
signalling in angiogenesis depends on context and specific ligand that ALK1 is 
activated by (Goumans, Liu et al. 2009). 
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6.3.2. Smads 
As described in chapter 2 Smads play an important role in the signalling cascade of the 
TGF-β pathway. Numerous studies investigated the role of BMPRII and its downstream 
signalling related to pulmonary hypertension, whereas of the downstream signalling of 
ALK1 in this relation not much is known.  
In a monocrotaline rodent model of experimental PAH it was shown that ALK1, TGF-
βR2, Endoglin as well as Smad3 and Smad4 expression was downregulated in PASMCs  
from animals that developed severe PAH, pointing to the idea that reduced expression 
of  components of the TGF-β family leads to impaired signalling (Zakrzewicz, Kouri et 
al. 2007). Yuan and Jing suggest Smad8 as a candidate gene for PAH since “pulmonary 
vasculature in association with Smad8 mutant was characterized by medial thickening 
and smooth muscle hyperplasia in distal pulmonary arteries in a mouse model similar to 
the changes in patients with pulmonary artery hypertension” (Yuan and Jing 2010).  
Due to the fact that Smads play an important role in the pathogenesis of pulmonary 
hypertension, Smad expression in hPASMCs was analysed after exposure to hypoxia by 
qRT-PCR. Of the investigated genes only Smad1 showed a significant downregulation 
after 6 hours of hypoxia compared to normoxia. This observation is limited since a PGK 
upregulation could not be found for hPASMCs exposed to hypoxia for 6 hours. 
Moreover, data obtained show the tendency of decreased expression of PGK after 
exposure to hypoxia for 6 hours. Interestingly, after an initial tendency of 
downregulation of expression after 6 hours exposure to hypoxia, all Smads investigated 
show the tendency of increasing expression compared to the data obtained after 6 hours 
of exposure to hypoxia. For Smads investigated on protein level no significant data was 
observed.  
 
6.3.3. Target genes 
As target genes for ALK1/ ALK5 ID1/ PAI-1 have been identified, respectively 
(Goumans, Valdimarsdottir et al. 2002). Also it has been shown that ALK1 upregulates 
ID2 (Ota, Fujii et al. 2002) (Lux, Salway et al. 2006). It could be shown by a few 
studies that ID proteins contribute to the regulation of the cell cycle. Investigations 
revealed that overexpression of ID2-cDNA leads to cell growth of SMCs in vitro. 
(Matsumura, Lobe et al. 2002). PAI-1 has been found to inhibit proliferation and 
enhance migration of PASMC (Kouri, Queisser et al. 2008), although Diebold, Kraicun 
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et al. state that depending on the circumstances PAI-1 can lead to both increase or 
decrease of vascular remodelling. In detail the vascular bed, type of lesion, experimental 
condition, clinical condition as well as the interaction of PAI-1 with different molecules 
are made responsible for the conflicting effects of PAI-1 on vascular remodelling 
(Diebold, Kraicun et al. 2008).  Lowery, Frump et al. could show that ID1 is 
upregulated with exposure to hypoxia in the pulmonary vasculature, and furthermore 
that the fraction of VSMCs expressing ID1 is enlarged (Lowery, Frump et al. 2010). In 
the study performed a significant increase of ID2 mRNA in hPASMCs exposed to 
hypoxia for 48 hours could be detected, which in context to Matsumura, Lobe et al. 
2002 might lead to cell growth. For PAI-1 and ID1 a general tendency of upregulation 
upon exposure to hypoxia compared to normoxia could be observed. Regarding 
literature and the results of this experiment, ID1 and ID2 as well as PAI-1 seem to be 
involved in the hypoxia regulated functions of the cell, although different approaches 
have been made. 
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6.4. Summing up and looking out 
Numerous studies have been performed around the topic of the TGF-β pathway, 
showing the importance and involvement of the members of the TGF-β family in basic 
processes in cells and organs. Still a lot of information waits to be discovered and needs 
to be put into context.  
In this study different aspects of the TGF-β pathway family members were investigated 
using hPASMCs cultivated under hypoxic and normoxic conditions. On mRNA level an 
altered expression of certain genes under hypoxic conditions could be shown while on 
protein level these observations could not be confirmed. Furthermore an influence of 
ALK1 on migration and proliferation could not be revealed.  
To clarify the role of the TGF-β family and especially ALK1 in this context, further 
experiments are necessary. 
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7. Summary 
Pulmonary arterial hypertension (PAH) is a rare but serious condition. In PAH 
abnormal proliferation of smooth muscle cells (SMCs) leads to a decreasing diameter of 
the vessel and an increase in resistance, resulting in an elevated pulmonary arterial 
pressure and right heart failure.  
PAH can be found as idiopathic, heritable or in association with multiple other 
conditions. This thesis focuses on PAH in context to the members of the transforming 
growth factor β  (TGF-β) family and especially activin receptor like kinase 1 (ALK1) in 
human pulmonary artery smooth muscle cells (hPASMCs), since mutations in the genes 
coding for the TGF-β family members BMPR-II and ALK1 have been linked to the 
development of PAH. To imitate PAH, cells were exposed to hypoxia as a stimulus of 
PAH.  
On mRNA level significant upregulation was observed for the TGF-β receptors ALK1 
and ALK5 after exposure of hPASMCs to hypoxia for 48 hours compared to the control 
group. The TGF-β receptors ALK2, ALK3, ALK4, ALK6, TGF-βRII, BMPRII and 
Endoglin also showed the tendency of upregulation after 48 hours exposure to hypoxia. 
Of the mediators of the TGF-β pathway Smad2 - Smad5 and Smad8 showed the 
tendency of increased mRNA expression after 48 hours exposure to hypoxia. Among 
the target genes of the TGF-β family members ID2 was significantly upregulated after 
48 hours exposure to hypoxia and ID1 as well as PAI-1 showed a general tendency of 
upregulation upon exposure to hypoxia. On protein level no significant changes in 
expression could be detected when comparing hypoxia to normoxia exposed cells. The 
proliferation assay of hPASMCs indicated that proliferation of not transfected 
hPASMCs takes place under hypoxic stimulation, while for ALK1 siRNA transfected 
cells no significant data could be shown. Furthermore ALK1 could be localised in the 
hPASMCs by immunofluorescence both under normoxic and hypoxic conditions. 
This work explores the characteristics of TGF-β pathway family members, especially 
the role of ALK1, in hPASMCs under hypoxia and normoxia. For some of the 
investigated genes, an altered expression under hypoxic conditions on mRNA level 
could be demonstrated, yet there were no corresponding changes on protein level. An 
influence of ALK1 on migration and proliferation of hPASMCS could not be shown. To 
further evaluate the impact of the TGF-β pathway family members on the behaviour of 
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hPASMCs under hypoxic and normoxic conditions, additional experiments need to be 
performed. 
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Zusammenfassung 
Pulmonale arterielle Hypertonie (PAH) ist eine seltene aber ernste Krankheit. Bei der 
PAH führt anomale Proliferation von glatten Muskelzellen (SMC) zu einer 
Verringerung des Gefäßdurchmessers und einer Zunahme des Widerstandes. Dies führt 
zu einem erhöhten pulmonalen arteriellen Druck sowie Rechtsherzversagen.  
PAH kann idiopathisch, erblich oder in Verbindung mit multiplen anderen Krankheiten 
vorkommen. Die vorliegende Arbeit untersucht den Zusammenhang zwischen 
Mitgliedern der  transforming growth factor β (TGF-β) Familie und insbesondere 
activin receptor like kinase 1 (ALK1) in humanen pulmonalen arteriellen glatten 
Muskelzellen (hPASMCs) und der PAH, da Mutationen in Genen, die für die TGF-β 
Familienmitglieder BMPRII und ALK1 kodieren, in Verbindung mit der Entwicklung 
einer PAH gebracht werden. Um eine PAH zu imitieren, wurden die Zellen Hypoxie als 
Stimulus zur Entwicklung einer PAH ausgesetzt.  
Nachdem die hPASMCs 48 Stunden Hypoxie ausgesetzt waren, konnte unter den TGF-
β Rezeptoren eine signifikante Hochregulation auf mRNA-Ebene für ALK1 und ALK5 
im Vergleich zur Kontrollgruppe beobachtet werden. Die  TGF-β Rezeptoren ALK2, 
ALK3, ALK4, ALK6, TGF-βRII, BMPRII und Endoglin tendierten ebenfalls zur 
Hochregulation nach 48 Stunden Hypoxieexposition. Unter den Mediatoren des TGF-β 
Signalweges zeigten sowohl Smad2 - Smad5 als auch Smad8 die Tendenz einer 
erhöhten mRNA Expression nach 48 Stunden Hypoxieexposition. Von den Zielgenen 
der TGF-β Familie zeigte sich ID2 nach 48 Stunden Hypoxieexposition signifikant 
hochreguliert, zudem zeigten ID1 als auch PAI-1 eine generelle Tendenz zur 
Hochregulation unter Hypoxieexposition. Auf Protein-Ebene konnten keine 
signifikanten Veränderungen der Expression im Vergleich von Normoxie zu Hypoxie 
gezeigt werden. Das Proliferationsassay der hPASMC zeigt, dass nicht transfizierte 
hPASMCs unter Hypoxie proliferieren, während für ALK1 siRNA transfizierte Zellen 
keine signifikanten Daten gezeigt werden konnte. Weiterhin konnte ALK1 sowohl unter 
hypoxischen als auch normoxischen Bedingungen in hPASMCs mittels 
Immunfluoreszenz dargestellt werden. 
Diese Arbeit untersucht die Rolle der Mitglieder der TGF-β Signalkette, insbesondere 
von ALK1, in hPASMCs unter Hypoxie und Normoxie. Für einige der untersuchten 
Gene konnte eine veränderte Expression auf mRNA-Ebene unter hypoxischen 
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Bedingungen gezeigt werden, jedoch konnten keine dementsprechenden Veränderungen 
auf Protein-Ebene nachgewiesen werden. Ein Einfluss von ALK1 auf die Migration und 
Proliferation von hPASMCs konnte nicht gezeigt werden. Um den möglichen Einfluss 
der Mitglieder der TGF-β Signalkaskade auf das Verhalten von hPASMCs unter 
Normoxie und Hypoxie besser beurteilen zu können, sind weitere Experimente 
erforderlich. 
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8. List of abbreviations 
 
ActR   activin receptor 
ALK   activin receptor-like kinase 
AMHR  anti-Muellerian hormone receptor 
APS   ammonium persulfate 
 
BMP   bone morphogenetic protein 
BMPR   bone morphogenetic protein receptor 
 
Cdk4   cyclin-dependent kinase 4 
cDNA   complementary deoxyribonucleic acid 
Co-Smad  collaborator Smad 
 
DAPI   4',6-diamidino-2-phenylindole 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleotide triphosphate 
 
EC   endothelial cell 
ECM   extracellular matrix 
EDTA   2,2',2'',2'''-(Ethane-1,2-diyldinitrilo) tetraacetic acid 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ET-1   endothelin-1 
 
FBS   fetal bovine serum 
FCS   fetal calf serum 
FITC   fluorescein-5-isothiocyanate 
 
GDF   growth differentiation factor 
HHT   hereditary hemorrhagic telangiectasia 
hPASMC  human pulmonary artery smooth muscle cell 
HRP   horseradish peroxidase 
List of abbreviations 
                                                                                                                                          58 
 
ID   inhibitor of differentiation 
Ig   immunoglobulin 
IPAH   idiopathic pulmonary arterial hypertension 
I-Smad  inhibitory Smad 
 
Ki67   antigen Ki67 
 
MMP   matrix metalloproteinase 
mRNA  messenger RNA 
 
NO   nitric oxide 
NP-40   nonylphenyl polyethylene glycol 
 
PAH   pulmonary arterial hypertension 
PAI-1   plasminogen activator inhibitor-1 
PBGD   porphobilinogen deaminase 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PGK   phosphoglycerate kinase  
PH   pulmonary hypertension 
PPH   primary pulmonary hypertension 
pSmad   phosphorylated Smad 
 
RNA   ribonucleic acid 
rpm   rounds per minute 
R-Smad  receptor-regulated Smad 
 
SDS   sodium dodecyl sulfate 
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